💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English

Andexanet Alfa

CHEMBL3301583 Phase 4 Approved Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A modified form of Factor Xa that acts as a decoy to bind and neutralize anticoagulant drugs such as apixaban and rivaroxaban during life-threatening bleeding events. It rapidly reverses the blood-thinning effects to help stop uncontrolled bleeding.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A modified form of Factor Xa that acts as a decoy to bind and neutralize anticoagulant drugs such as apixaban and rivaroxaban during life-threatening bleeding events. It rapidly reverses the blood-thinning effects to help stop uncontrolled bleeding.

Yes, Andexanet Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301583. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.